EOFLOW v Insulet (CoA, 9 October 2024)
| Date | 9 October 2024 |
|---|---|
| Court | CoA |
| Division | Luxembourg (LU) |
| Type of action | Generic Order |
| Registry reference | ORD_55415/2024 |
| Parties | EOFLOW Co., Ltd. v. Insulet Corporation |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In an order of 9 October 2024 (UPC_CoA_584/2024), the Court of Appeal refused EOFlow’s request to expedite its appeal against the order of 24 September 2024 of the Milan Central Division, which had declined to join Insulet’s application for provisional measures against EOFlow (EP 4 201 327) with its parallel application against Menarini before the Milan Local Division. With oral hearings listed for 15 and 16 October 2024, a ruling beforehand would have meant cutting Insulet’s time to respond substantially. The order shows that a party which is slow to come to the Court bears the cost of its own delay.
Question
Should the Court of Appeal expedite the appeal and shorten the respondent’s 15-day period for replying to the statement of grounds of appeal?
Decision
The request was admissible (paragraph 11). Rule 9.3(b) allows a time period to be shortened on a reasoned request, but EOFlow’s arguments did not outweigh Insulet’s interests and the requirements of due process (paragraphs 13 to 15). EOFlow had not explained why it waited for the decision on Menarini’s intervention before appealing. Its ten-day delay would require Insulet’s time to be cut substantially, although EOFlow itself had taken longer than the time Insulet would be left with (paragraphs 16 and 17). Given the outcome, the Court ruled without hearing Insulet (paragraph 12).
Key points for practice
- Expedition of an appeal under Rules 9.3(b) and 225(e) depends on the applicant’s own diligence: a late appeal does not justify curtailing the other side’s time to respond (paragraphs 16 and 17).
Provisions applied
- Rules of Procedure
- Rules 9.3(b), 224.2(b), 225(e), 235, 333 and 340.1
- Case law cited
- No UPC decision is cited.
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- defendantInsulet Corporation26 decisions in the corpusFollow this party
- claimantEOFLOW Co., Ltd.22 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Generic Order
- Outcome (Dhenne Avocats summary)
- La cour d’appel refuse d’accélérer l’appel d’EOFlow contre le refus de jonction et d’abréger le délai de réponse d’Insulet, faute pour EOFlow d’avoir justifié son propre retard.
- Appeal
- Decision of the Court of Appeal.
- Instance
- Court of Appeal decision.
Patents mentioned
EP 4 201 327mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Angelalign Technology v Align Technology (CoA, 6 January 2026) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 201 327Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith recorded proprietor: Insulet Corp | Mentioned in the analysis (role not qualified) Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.